Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 25 July, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo

Fundamental Analysis of RPG Life Sciences Ltd

Basic Stock Data

Last Updated: July 24, 2024, 10:41 pm

Market Cap 3,347 Cr.
Current Price 2,025
High / Low2,066/1,010
Stock P/E36.3
Book Value 227
Dividend Yield0.79 %
ROCE34.6 %
ROE25.5 %
Face Value 8.00
PEG Ratio1.47

Data Source: screener.in

Competitors of RPG Life Sciences Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Murae Organisor Ltd 36.3 Cr. 1.473.10/0.90727 2.260.00 %0.79 %0.13 % 2.00
Dipna Pharmachem Ltd 18.3 Cr. 7.6024.1/7.4616.8 15.60.00 %8.49 %4.47 % 10.0
Decipher Labs Ltd 18.5 Cr. 18.325.8/14.4 21.60.00 %4.30 %7.46 % 10.0
Coral Laboratories Ltd 250 Cr. 700748/24515.7 4970.00 %12.6 %9.58 % 10.0
Concord Drugs Ltd 38.4 Cr. 38.461.5/28.291.4 33.80.00 %4.54 %1.29 % 10.0
Industry Average21,646.60 Cr1,325.9460.92208.570.34%17.22%16.89%6.46

Quarterly Result

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Sales93108113116104129135131118148154154127
Expenses8085879190101105101103116116116106
Operating Profit13232624142830291632373821
OPM %14%21%23%21%13%22%22%22%13%22%24%25%16%
Other Income0011111122222
Interest0000000000000
Depreciation4444444444444
Profit before tax9192221112527261430353618
Tax %23%30%30%29%31%28%26%26%25%26%26%26%25%
Net Profit714161581820191022262613
EPS in Rs4.188.219.528.854.5511.0112.0711.556.2613.3615.6416.008.01

Last Updated: July 10, 2024, 9:20 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: July 10, 2024, 9:20 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Sales222236242279294344330376389440513582
Expenses206224228256274306296315318353408454
Operating Profit16121423203834607187104128
OPM %7%5%6%8%7%11%10%16%18%20%20%22%
Other Income266111811-51347
Interest733245532110
Depreciation101111101114151616161617
Profit before tax16511223201536547392118
Tax %-717%18%0%0%10%34%28%20%25%30%26%26%
Net Profit4531122113112940516888
EPS in Rs2.6732.290.607.0312.708.136.5417.5424.1931.1340.9053.00
Dividend Payout %45%6%132%23%22%30%37%23%30%31%29%30%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)1225.00%-98.11%1100.00%75.00%-38.10%-15.38%163.64%37.93%27.50%33.33%29.41%
Change in YoY Net Profit Growth (%)0.00%-1323.11%1198.11%-1025.00%-113.10%22.71%179.02%-125.71%-10.43%5.83%-3.92%

Growth

Compounded Sales Growth
10 Years:9%
5 Years:12%
3 Years:14%
TTM:13%
Compounded Profit Growth
10 Years:37%
5 Years:52%
3 Years:30%
TTM:29%
Stock Price CAGR
10 Years:35%
5 Years:56%
3 Years:62%
1 Year:92%
Return on Equity
10 Years:17%
5 Years:23%
3 Years:24%
Last Year:25%

Last Updated: July 25, 2024, 6:14 am

Balance Sheet

Last Updated: July 10, 2024, 9:20 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Equity Capital131313131313131313131313
Reserves63113112120134142147163203243294362
Borrowings63153323455436122100
Other Liabilities67563949558254788588112138
Total Liabilities206196197205247291251267303345419513
Fixed Assets103106105109137131128123113104124125
CWIP111229171012312585
Investments00000000005891
Other Assets102899294108152106134178210211212
Total Assets206196197205247291251267303345419513

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity 12-6-233715465058659194
Cash from Investing Activity -1259-10-15-30-16-19-11-8-35-106-79
Cash from Financing Activity -0-5412-18230-26-39-10-14-17-20
Net Cash Flow00-0-01-1004017-32-5

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-47.00-3.00-19.000.00-25.00-16.00-2.0048.0069.0086.00104.00128.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days815661484972436254272731
Inventory Days140180149156163171136133162214203200
Days Payable22617610913510216583127132117138140
Cash Conversion Cycle-56010170110789668841249190
Working Capital Days465176545062534653473382
ROCE %6%2%2%9%10%13%10%23%27%31%33%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Promoters72.07%72.07%72.07%72.07%72.41%72.62%72.62%72.82%72.82%72.82%72.82%72.82%
FIIs0.00%0.02%0.20%0.12%0.15%0.08%0.25%0.38%0.33%0.46%0.56%0.90%
DIIs0.01%0.01%0.01%0.01%0.01%0.03%0.01%0.11%0.27%1.57%1.77%2.16%
Public27.92%27.90%27.72%27.80%27.43%27.27%27.11%26.70%26.58%25.15%24.85%24.12%
No. of Shareholders20,56423,67422,76822,82122,11520,75721,36020,83720,22621,08821,86622,137

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Mirae Asset Multicap Fund165,2691.1822.98472024-07-21351536.17%
Motilal Oswal S&P BSE Healthcare ETF470.070.01472024-07-210%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue8.008.008.008.008.00
Basic EPS (Rs.)53.0140.9031.1324.1917.54
Diluted EPS (Rs.)53.0140.9031.1324.1917.54
Cash EPS (Rs.)63.3350.2740.6034.1527.43
Book Value[Excl.RevalReserv]/Share (Rs.)226.67186.00154.66130.88106.77
Book Value[Incl.RevalReserv]/Share (Rs.)226.67186.00154.66130.88106.77
Dividend / Share (Rs.)16.0012.009.607.204.00
Revenue From Operations / Share (Rs.)351.96310.09266.16235.31227.10
PBDIT / Share (Rs.)81.8565.0054.0342.8436.21
PBIT / Share (Rs.)71.5355.6244.5632.8826.32
PBT / Share (Rs.)71.2655.4444.2432.4022.04
Net Profit / Share (Rs.)53.0140.9031.1324.1917.54
PBDIT Margin (%)23.2520.9620.2918.2015.94
PBIT Margin (%)20.3217.9316.7413.9711.58
PBT Margin (%)20.2417.8716.6213.769.70
Net Profit Margin (%)15.0613.1911.6910.277.72
Return on Networth / Equity (%)23.3821.9820.1218.4816.42
Return on Capital Employeed (%)30.9729.0527.8624.3023.63
Return On Assets (%)17.0916.1214.9313.1810.87
Long Term Debt / Equity (X)0.000.000.000.000.01
Total Debt / Equity (X)0.000.000.000.010.03
Asset Turnover Ratio (%)1.251.341.361.371.45
Current Ratio (X)2.282.572.582.211.52
Quick Ratio (X)1.501.641.551.470.95
Inventory Turnover Ratio (X)1.230.961.251.631.71
Dividend Payout Ratio (NP) (%)22.6423.4723.130.0036.50
Dividend Payout Ratio (CP) (%)18.9519.1017.730.0023.34
Earning Retention Ratio (%)77.3676.5376.870.0063.50
Cash Earning Retention Ratio (%)81.0580.9082.270.0076.66
Interest Coverage Ratio (X)300.80346.74171.8389.6734.22
Interest Coverage Ratio (Post Tax) (X)195.80219.19100.0051.6320.62
Enterprise Value (Cr.)2494.101093.81855.55600.68287.41
EV / Net Operating Revenue (X)4.292.131.941.540.76
EV / EBITDA (X)18.4310.189.588.484.80
MarketCap / Net Operating Revenue (X)4.352.242.101.650.75
Retention Ratios (%)77.3576.5276.860.0063.49
Price / BV (X)6.753.743.622.961.60
Price / Net Operating Revenue (X)4.352.242.101.650.75
EarningsYield0.030.050.050.060.10

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value: 2,117.83

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Undervalued: 4.58% compared to the current price 2025

Intrinsic Value: 2,642.04

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Undervalued: 30.47% compared to the current price 2025

Last 5 Year EPS CAGR: 24.75%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The company has higher reserves (174.67 cr) compared to borrowings (23.67 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (353.92 cr) and profit (42.50 cr) over the years.
  1. The stock has a low average ROCE of 13.83%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 54.42, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 80.58, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in RPG Life Sciences Ltd:
    1. Net Profit Margin: 15.06%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 30.97% (Industry Average ROCE: 17.22%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ✓ ROE%: 23.38% (Industry Average ROE: 16.89%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 195.80
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.50
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. ✓ Stock P/E: 36.3 (Industry average Stock P/E: 60.91)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. ✓ Total Debt / Equity: 0.00
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company

RPG Life Sciences Ltd. is a Public Limited Listed company incorporated on 29/03/2007 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24232MH2007PLC169354 and registration number is 169354. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 440.16 Cr. and Equity Capital is Rs. 13.23 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsRPG House, Mumbai Maharashtra 400030investorservices@rpgls.com
http://www.rpglifesciences.com
Management
NamePosition Held
Mr. Harsh V GoenkaChairman
Mr. Yugal SikriManaging Director
Mr. Rajat BhargavaNon Executive Director
Mr. Sachin NandgaonkarIndependent Director
Mr. Manoj K MaheshwariIndependent Director
Mr. Narendra AmbwaniIndependent Director
Ms. Zahabiya KhorakiwalaIndependent Director
Mr. Bhaskar IyerIndependent Director
Dr. Lalit S KanodiaIndependent Director
Mr. Mahesh S GuptaIndependent Director
Mr. Hiten KotakIndependent Director
Mr. Anil MataiIndependent Director
Ms. Radhika GuptaIndependent Director

FAQ

What is the latest fair value of RPG Life Sciences Ltd?

The latest fair value of RPG Life Sciences Ltd is ₹2117.83.

What is the Market Cap of RPG Life Sciences Ltd?

The Market Cap of RPG Life Sciences Ltd is 3,347 Cr..

What is the current Stock Price of RPG Life Sciences Ltd as on 25 July 2024?

The current stock price of RPG Life Sciences Ltd as on 25 July 2024 is 2,025.

What is the High / Low of RPG Life Sciences Ltd stocks in FY 2024?

In FY 2024, the High / Low of RPG Life Sciences Ltd stocks is 2,066/1,010.

What is the Stock P/E of RPG Life Sciences Ltd?

The Stock P/E of RPG Life Sciences Ltd is 36.3.

What is the Book Value of RPG Life Sciences Ltd?

The Book Value of RPG Life Sciences Ltd is 227.

What is the Dividend Yield of RPG Life Sciences Ltd?

The Dividend Yield of RPG Life Sciences Ltd is 0.79 %.

What is the ROCE of RPG Life Sciences Ltd?

The ROCE of RPG Life Sciences Ltd is 34.6 %.

What is the ROE of RPG Life Sciences Ltd?

The ROE of RPG Life Sciences Ltd is 25.5 %.

What is the Face Value of RPG Life Sciences Ltd?

The Face Value of RPG Life Sciences Ltd is 8.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in RPG Life Sciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE